- Synplogen, a synthetic biology startup spun out of Kobe University's Graduate School of Science, Technology and Innovation that provides custom DNA synthesis and Gene Therapy Biofoundry™ services, has entered into a non-binding Memorandum of Understanding ("MOU") with Ginkgo Bioworks with the intent to advance global DNA manufacturing and gene therapy platform services within the Japanese market
- Synplogen intends to support and introduce Ginkgo's gene therapy services within the Japanese biotechnology and pharmaceutical ecosystem
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.